Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CID-103 in adults with persistent or chronic immune thrombocytopenia
CTR20244168Phase 2Active
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CID-103 in immune thrombocytopenia (ITP), sponsored by CASI Pharmaceuticals, Inc.. Started Jan 2025; status: active.
02
Drugs
CID-103
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20244168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244168.